---
title: Assess propofol effects on brain
nct_id: NCT05895019
status: RECRUITING
sponsor: Beijing Tiantan Hospital
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05895019"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05895019"
last_fetched: "2026-05-10T14:08:22.516Z"
source: "Parkinson's Pathways (curated)"
---
# Assess propofol effects on brain

**Goal (in five words):** Assess propofol effects on brain

**Official Title:** Effects of Propofol on Brain Function in Patients With Parkinson's Disease

**Trial ID:** [NCT05895019](https://clinicaltrials.gov/study/NCT05895019)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Beijing Tiantan Hospital
- **Target Enrollment:** 600 participants
- **Start Date:** 2023-06-01
- **Completion Date:** 2025-09-30
- **Conditions:** PD - Parkinson's Disease
- **Interventions:** Propofol
- **Intervention Types:** DRUG

## Summary For Families

They are looking at how propofol, the common anesthetic that enhances GABA-A activity and quiets brain electrical signals, changes brain function in people with Parkinson's, especially during procedures like bilateral deep brain stimulation. It's an observational study where propofol is given during surgery and researchers record how it alters neuronal activity; propofol does not boost or block dopamine like levodopa, but by suppressing neural firing it can change the brain signals clinicians rely on for DBS and may affect how symptoms or recordings appear under anesthesia. The trial enrolls adults 18 to 80 years old, ASA class I to III, including people with primary or genetic PD who still respond well to levodopa and are scheduled for bilateral DBS, plus a comparison group of adults without neurological disease having non-neurosurgical, non-cardiac operations, with exclusions for severe sleep apnea, BMI over 30, difficult airways, serious organ failure, or prior major brain injury.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

PD group:

1. age 18-80 years, ASA class I-III, proposed bilateral DBS surgery;
2. primary PD, or hereditary PD, various genotypes of PD, responding well to compounded levodopa;
3. informed consent obtained;

Non-PD group:

1. age 18-80 years, ASA class I-III, proposed non-neurosurgical non-cardiac surgery;
2. no previous clearly diagnosed neurological disease or neurological dysfunction;
3. informed consent obtained.

Exclusion Criteria:

1. Obstructive sleep apnea;
2. BMI \> 30kg/m2;
3. Estimated difficult airway;
4. Patients with prior allergy to anesthetic drugs;
5. Serious dysfunction of important organs (i.e. heart failure, renal or liver dysfunction);
6. Patients with craniocerebral trauma or craniocerebral operation history resulting in incomplete skull or brain parenchyma defect;
7. Patients with alcohol or drug addiction.
```

## Locations (1)

- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Ruquan Han, M.D., Ph.D — (CONTACT) — 8610-59976660 — ruquan.han@gmail.com

## Central Contacts

- Ruquan Han, MD, PhD — (CONTACT) — 8610-59976660 — ruquan.han@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT05895019*  
*HTML version: https://parkinsonspathways.com/trial/NCT05895019*  
*Source data: https://clinicaltrials.gov/study/NCT05895019*